Alsaddi, Z.; Younis, O.; Khasawneh, G.; Shatnawi, Y.; Ahmed, N.; Jafari, Z.M.; Mushtaq, M.U.; Abdallah, A.-O.; Atrash, S.; Paul, B.
Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials. Cancers 2025, 17, 3730.
https://doi.org/10.3390/cancers17233730
AMA Style
Alsaddi Z, Younis O, Khasawneh G, Shatnawi Y, Ahmed N, Jafari ZM, Mushtaq MU, Abdallah A-O, Atrash S, Paul B.
Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials. Cancers. 2025; 17(23):3730.
https://doi.org/10.3390/cancers17233730
Chicago/Turabian Style
Alsaddi, Zain, Osama Younis, Ghena Khasawneh, Yara Shatnawi, Nausheen Ahmed, Zahra Mahmoud Jafari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Shebli Atrash, and Barry Paul.
2025. "Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials" Cancers 17, no. 23: 3730.
https://doi.org/10.3390/cancers17233730
APA Style
Alsaddi, Z., Younis, O., Khasawneh, G., Shatnawi, Y., Ahmed, N., Jafari, Z. M., Mushtaq, M. U., Abdallah, A.-O., Atrash, S., & Paul, B.
(2025). Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials. Cancers, 17(23), 3730.
https://doi.org/10.3390/cancers17233730
